

## RESEARCH ARTICLE

## Comparative study of oral iron and intravenous iron sucrose for the treatment of iron-deficiency anemia in pregnancy

Savitha A<sup>1</sup>, Saritha H<sup>2</sup>, Uma Deshmukh<sup>2</sup>, Swetha K<sup>3</sup><sup>1</sup>Department of Pharmacology, Bidar Institute of Medical Sciences, Bidar, Karnataka, India, <sup>2</sup>Department of Obstetrics and Gynecology, Bidar Institute of Medical Sciences, Bidar, Karnataka, India, <sup>3</sup>Department of Pharmacology, Karwar Institute of Medical Sciences, Karwar, Karnataka, India

Correspondence to: Swetha K, E-mail: drswethak27@gmail.com

Received: April 12, 2024; Accepted: May 01, 2024

## ABSTRACT

**Background:** The most prevalent nutritional disorder during pregnancy is iron-deficiency anemia (IDA). Management of anemia can be done by either oral, parenteral, or blood transfusion, depending on the severity. Oral iron (OI) replacements can be taken as they are safe, effective, and lower cost. However, one disadvantage is poor tolerability, as they cause gastrointestinal complications. Iron sucrose complex is a relatively new drug used intravenously (IV) for the correction of IDA. **Aims and Objectives:** This research compared the safety and effectiveness of OI versus iron sucrose in the treatment of IDA during pregnancy. **Materials and Methods:** A prospective observational study was performed involving 60 patients who attended the antenatal clinic from June 2019 to November 2019 at Bidar Institute of Medical Science between 24 and 36 weeks of gestation and hemoglobin levels between 7 and 10 g/dL. In the IV group, 200 mg of iron sucrose was administered in 100 mL of 0.9% normal saline over 15–20 min on alternate days. In the oral group, 200 mg of ferrous ascorbate per day for 4 weeks was prescribed. All patients were monitored for laboratory responses and adverse effects. An unpaired “t” test was used for statistical analysis.  $P < 0.05$  was considered significance. **Results:** There was an increase in hemoglobin in both groups, but there was a significant increase in hemoglobin in the IV group. The other laboratory parameters also showed a significant increase in the IV group than in the oral group. The IV group had no major side effects. **Conclusion:** The IV iron sucrose formulation was more effective than the oral formulation for anemia correction in pregnancy.

**KEY WORDS:** Iron-Deficiency Anemia of Pregnancy; Iron Sucrose; Ferrous Ascorbate

## INTRODUCTION

The most prevalent nutritional disorder during pregnancy is iron-deficiency anemia (IDA). It is one of the major health problems in the world. The World Health Organization defines anemia as hemoglobin (Hb)  $<11$  g%, and it has reported

35–75% anemia prevalence in developing countries,<sup>[1]</sup> of which 65–75% is in India.<sup>[2]</sup> The etiology of anemia could be poor nutrition, iron deficiency, malaria, worm infestations, HIV infection, and hemoglobinopathies<sup>[3]</sup> An adverse obstetric outcome is typically one of the consequences of anemia.<sup>[4]</sup> In addition, it causes 20% of maternal deaths. It was noted that anemia was an indirect reason for maternal death in about 20–40% of the patients.<sup>[5]</sup>

Management of anemia can be done by either oral, parenteral, or blood transfusion, depending on the severity.<sup>[6]</sup> Blood transfusions have their own disadvantages, such as transfusion reactions, anaphylaxis, and infection transmission (such as HIV, hepatitis B surface antigen, and cytomegalovirus).

## Access this article online

Website: [www.njppp.com](http://www.njppp.com)

Quick Response code

DOI: 10.5455/njppp.2024.14.04177202401052024



National Journal of Physiology, Pharmacy and Pharmacology Online 2024. © 2024 Swetha K, *et al.* This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

Thus, oral iron (OI) replacements can be taken as they are safe, effective, and lower cost. However, one disadvantage is poor tolerability, as they cause gastrointestinal (GI) complications.<sup>[7]</sup> Iron sucrose complex is a relatively new drug used for IDA correction intravenously (IV).<sup>[8]</sup>

This study was conducted to compare IV iron with OI in the management of IDA during 24–36 weeks of gestation in pregnancy.

## MATERIALS AND METHODS

A prospective observational study was carried out at the Obstetrics and Gynecology Department, Bidar Institute of Medical Sciences Teaching Hospital, from June 2019 to November 2019. All pregnant women between 24 and 36 weeks attending the antenatal clinic were enrolled. The inclusion criteria included singleton uncomplicated pregnancy, gestational age between 24 and 36 weeks, Hb between 7 and 10 g/dL, and age between 18 and 40 years.

Exclusion criteria included being allergic to parenteral iron, patient with Hb <7 and >10 g/dL, having a history of bleeding disorders, hemoglobinopathies, any acute or chronic infection, any obstetric complications, and any history of recent blood transfusion.

After taking consent, an examination and investigation were done. Ethical clearance was taken.

A total of 60 patients who satisfied the inclusion and exclusion criteria were enrolled, and based on the treatment given by the obstetrician, they were divided into 2 groups: A and B. Group “A” OI group and Group “B” IV iron (IVI) group. In group A, patients received 2 tablets of ferrous ascorbate each containing 100 mg of elemental iron daily for 4 weeks. It was advised that women should take the tablets with an empty stomach and not take milk, tea, or coffee after taking the tablets. Hb was repeated at 2, 4, and 6 weeks after the beginning of oral treatment. In group “B”, the parenteral iron sucrose dose was calculated by:

Total dose = weight in kilograms (target Hb in g/dL–actual Hb) × 0.24 + 500 mg.

Iron sucrose was administered as 200 mg (elemental iron) in 100 mL of 0.9% normal saline IV over 15–20 min on alternate days. Along with this, folic acid supplements were given to prevent its deficiency. During this period, the use of OI was withheld.

The two groups were monitored clinically for any adverse reactions. Laboratory investigations such as hemoglobin%, complete blood picture, peripheral smear for types of anemia, and urine analysis were carried out on day 1 and on stipulated follow-up.

Statistical analysis was done by calculating the mean ± standard deviation. To determine the statistical significance between the two groups, the student T unpaired test was utilized.

## RESULTS

Among the 60 enrolled pregnant patients, there were 9 dropouts in the OI group and 6 dropouts in the IVI group. Both groups baseline clinical and demographic characteristics were comparable [Tables 1 and 2]. In the OI group, 46.66% showed adverse reactions, while in the IV group, 13.3% showed adverse reactions. No major anaphylactic reactions were noted with iron sucrose [Table 3].

## DISCUSSION

IDA is one of the most widespread of all nutritional deficiencies in pregnancy. In this study, the safety, efficacy, and tolerability of OI were compared to IV iron sucrose in treating IDA in pregnancy. Moreover, it was found that IV iron sucrose elevates Hb and restores iron better than ferrous ascorbate [OI] in a short time. This was also observed in other studies conducted by Bayoumeu *et al*<sup>[6-9]</sup> and others.

As the rate of increase of Hb is faster with IV iron sucrose, it is suitable to use even in the third trimester.

OI is inexpensive, safe, and efficient; however, non-compliance has been seen because of GI side effects. About 10–40% of patients suffer diarrhea, constipation, discomfort, nausea, and severe abdominal pain.<sup>[10]</sup> Our study showed 60% of side effects in the OI group. Among the parenteral iron iron-dextran compounds given intramuscularly, they cause pain, injection site staining, and arthralgia.<sup>[11]</sup> It is not recommended for those with rheumatoid arthritis since it is linked to arthritis flare-ups. Another IM iron, the iron sorbitol citric acid complex produces nausea, vomiting, pain at the injection site, and a metallic taste.<sup>[2]</sup> Ferric citrate and ferric gluconate are other iron preparations that were discovered to cause severe extended liver necrosis.<sup>[12]</sup>

**Table 1:** Comparison of demographic characteristics in the two groups

| Characteristics          | Oral iron group (n=30) | Intravenous iron group (n=30) |
|--------------------------|------------------------|-------------------------------|
| Age (years)              | 26                     | 26                            |
| Body mass index (kg/sqm) | 21.5±3.81              | 22.6±3.59                     |
| Primigravida             | 20                     | 10                            |
| Multigravida             | 10                     | 20                            |
| Single gestation         | 30                     | 30                            |
| Second trimester         | 24                     | 23                            |
| Third trimester          | 6                      | 7                             |

| Table 2: Comparison of laboratory investigations pre- and post-treatment in two groups |               |             |         |                |                |         |
|--|---------------|-------------|---------|----------------|----------------|---------|
| Baseline   | Pre-treatment |             |         | Post-treatment |                |         |
|  | Oral          | IV          | P-value | Oral           | IV             | P-value |
| Hemoglobin (g/dL)  | 8.347±0.355   | 8.257±0.342 | 0.3251  | 9.2833±0.5173  | 10.0037±0.5128 | <0.0001 |
| packed cell volume (%)   | 28.18±1.932   | 27.21±1.902 | 0.0548  | 32.07±0.992    | 33.87±0.959    | <0.0001 |
| Mean corpuscular volume (fl)   | 80.26±1.459   | 79.52±1.583 | 0.0652  | 80.98±1.982    | 82.08±1.899    | 0.0322  |
| Mean corpuscular hemoglobin (picogram)   | 25.21±0.965   | 24.79±0.871 | 0.082   | 27.9±0.569     | 29.76±0.675    | <0.0001 |
| Mean corpuscular hemoglobin concentration (g/dL)                                       | 31.00±1.231   | 30.40±1.345 | 0.0767  | 33.41±1.223    | 33.36±1.047    | 8.8655  |

| Table 3: Adverse reaction with oral and intravenous iron |      |             |
|--|------|-------------|
| Adverse reactions  | Oral | Intravenous |
| NV   | 8    | 0           |
| Constipation   | 6    | 0           |
| Fever/chills   | 0    | 1           |
| Rashes   | 0    | 0           |
| Dizziness  | 0    | 2           |
| Thrombophlebitis   | 0    | 1           |
| Total  | 14   | 4           |

NV: Nausea and vomiting

Iron sucrose is a medium iron complex with a molecular weight of 30,000–1,00,000 Daltons. It is found to be very effective in regulating marrow proliferation. The half-life is 5–6 h and rapidly distributed.<sup>[13]</sup>

The rise in Hb was faster with iron sucrose use than with OI or IM iron-dextran.<sup>[14]</sup> In our study, iron sucrose was well accepted and was found to have 13.3% of adverse effects.

CONCLUSION

There was an increase in Hb in the two groups, but there was a significant increase in the Hb in IV iron sucrose groups. The other laboratory parameters also showed a significant increase in Hb in the IV iron sucrose group than in the OI group. The IV group had no major adverse effects. It was concluded from this study that IV iron sucrose was superior to OI in terms of effectiveness than OI for correction of anemia in pregnancy.

ACKNOWLEDGMENT

We would like to thank Dr. Ankita Bist for her help and support in statistical analysis.

REFERENCES

1. World Health Organization (WHO). The Prevalence of Anaemia in Women: A Tabulation of Available Information. 2<sup>nd</sup> ed. Geneva: World Health Organization; 1992.

2. Kalaivani K. Prevalence and consequences of anemia in

pregnancy. Indian J Med Res 2009;130:627-33.

3. UNICEF/UNO/WHO. Iron Deficiency Anemia. Geneva: World Health Organization; 2001.

4. Misra R. Ian Donald’s Practical Obstetric Problems. 7<sup>th</sup> ed. India: Wolters Kluwer India Pvt. Ltd; 2014. p. 198.

5. Maternal Mortality in India 1997-2003, Registrar General of India. Available from: <http://www.censusindia.net> [Last accessed on 2008 Dec 15].

6. Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: Intravenous route versus oral route. Am J Obstet Gynecol 2002;186:518-22.

7. Sharma JB, Soni D. Oxidative stress in pregnancy - role of iron therapy: Oral iron therapy and risk of free radicals. Obstet Gynecol 2001;6:705-6.

8. Perewusnyk KG, Huch R, Huch A, Breymann C. Parenteral iron therapy in obstetrics: 8 years’ experience with iron-sucrose complex. Br J Nutr 2002;88:3-10.

9. Al-Momen AK, Al-Meshari A, Al-Nuaim L, Saddique A, Abotalib Z, Khashoggi T, *et al.* Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1996;69:121-4.

10. Barut A, Harma M. Intravenous iron treatment for iron deficiency anaemia in pregnancy. J Turk Ger Gynecol Assoc 2009;10:109-15.

11. Kumar A, Jain S, Singh NP, Singh T. Oral versus high dose parenteral iron supplementation in pregnancy. Int J Gynaecol Obstet 2005;89:7-13.

12. Bashiri A, Burstein E, Sheiner E, Mazor M. Anemia during pregnancy and treatment with intravenous iron: Review of the literature. Eur J Obstet Gynecol Reprod Biol 2003;110:2-7.

13. Sharma JB, Jain S, Mallika V, Singh T, Kumar A, Arora R, *et al.* A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women. Am J Clin Nutr 2004;79:116-22.

14. Ragip A, Unlubilgin E, Kandermir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy. Obstet Gynecol 2005;106:1335-40.

**How to cite this article:** Savitha A, Saritha H, Deshmukh U, Swetha K. Comparative study of oral iron and intravenous iron sucrose for the treatment of iron-deficiency anemia in pregnancy. Natl J Physiol Pharm Pharmacol 2024;14(10):2048-2050.

**Source of Support:** Nil, **Conflicts of Interest:** None declared.